Akebia Therapeutics Inc. (AX9)
FSX
Delayed Data
Oct 23, 2026, 06:00 AM
Day's Range
0.494452 wk Range
0.4944Overview - AX9 - Akebia Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
227.11M
P/E (Trailing)
-34.97
P/E (Forward)
-0.89
Price / Sales (TTM)
0.88
Price / Book
8.51
EV / EBITDA
-59.22
Profitability
Gross Margin
78.78%
Profit Margin
-13.54%
Operating Margin
-5.45%
Return on Assets
-1.05%
Return on Equity
-109.38%
Ownership
Shares Outstanding
271.74M
Float
272.25M
Held by Insiders
1.98%
Held by Institutions
40.77%
Price stats
Beta
0.18
50-Day Avg
0.7988
200-Day Avg
1.01
Market Cap - AX9 - Akebia Therapeutics Inc.
Peers - AX9 - Akebia Therapeutics Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on FSX.
Profile Summary - AX9 - Akebia Therapeutics Inc.
About
Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for people living with kidney disease. Its current product portfolio centers on treatments for chronic kidney disease-related complications, including anemia management and phosphorus control, supported by a…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
